Blood:多发性骨髓瘤克隆进化和扩散的特征

2020-11-17 MedSci原创 MedSci原创

克隆进化驱动多发性骨髓瘤(MM)的肿瘤进展、扩散和复发,大多数患者死于复发疾病。这一多阶段过程需要肿瘤细胞进入血液循环、渗出和定植到远处骨髓(BM)中。

克隆进化驱动多发性骨髓瘤(MM)的肿瘤进展、扩散和复发,大多数患者死于复发疾病。这一多阶段过程需要肿瘤细胞进入血液循环、渗出和定植到远处骨髓(BM)中。

在《Blood》近日发表的“Progression signature underlies clonal evolution and dissemination of multiple myeloma”研究中,研究人员在MM PrEDiCT异种移植小鼠模型上开发了一个荧光或DNA条形码克隆跟踪系统,用以研究BM微环境中的克隆行为。

荧光标注的MM细胞的骨髓扩散模型

研究显示,只有少数能成功适应BM微环境的克隆才能进入血液循环,并在远距离的BM中定植。对原发和远处MM细胞的RNA测序显示,随着人MM的进展,进展信号被依次激活;当对照患者数据集进行评估时,该信号与总存活率显著相关。

HMGA1和PA2G4在不同样本中的表达

通过计算,预测了28个基因可能是MM进展的主调节基因(MRS)。通过CRISPR/Cas9在PrEDiCT模型体内验证了HMGA1和PA2G4;还发现HMGA1和PA2G4在远处骨髓部位明显缺失,提示它们在MM的进展和扩散中起作用。此外,HMGA1和PA2G4的缺失也影响了MM细胞的增殖、迁移和黏附能力。

总体而言,该研究模型成功地概括了人类MM疾病进展的关键特征,并确定了MM潜在的新治疗靶点。

原始出处:

Shen Yu Jia,Mishima Yuji,Shi Jiantao et al. Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood, 2020. https://doi.org/10.1182/blood.2020005885

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1984524, encodeId=e882198452499, content=<a href='/topic/show?id=7c802892e76' target=_blank style='color:#2F92EE;'>#克隆进化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28927, encryptionId=7c802892e76, topicName=克隆进化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Mon Oct 04 08:35:35 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660235, encodeId=595e1660235d1, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Mon Sep 06 12:35:35 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890184, encodeId=5526189018470, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Apr 11 14:35:35 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900358, encodeId=ae089003584a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/f548240d8bfc479980e63d1c1ca03b30/97576fe32da94dcfbf18dbeb0af5b025.jpg, createdBy=efb62405528, createdName=亚亚Doris, createdTime=Thu Nov 19 08:15:21 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1984524, encodeId=e882198452499, content=<a href='/topic/show?id=7c802892e76' target=_blank style='color:#2F92EE;'>#克隆进化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28927, encryptionId=7c802892e76, topicName=克隆进化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Mon Oct 04 08:35:35 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660235, encodeId=595e1660235d1, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Mon Sep 06 12:35:35 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890184, encodeId=5526189018470, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Apr 11 14:35:35 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900358, encodeId=ae089003584a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/f548240d8bfc479980e63d1c1ca03b30/97576fe32da94dcfbf18dbeb0af5b025.jpg, createdBy=efb62405528, createdName=亚亚Doris, createdTime=Thu Nov 19 08:15:21 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2021-09-06 aids221
  3. [GetPortalCommentsPageByObjectIdResponse(id=1984524, encodeId=e882198452499, content=<a href='/topic/show?id=7c802892e76' target=_blank style='color:#2F92EE;'>#克隆进化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28927, encryptionId=7c802892e76, topicName=克隆进化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Mon Oct 04 08:35:35 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660235, encodeId=595e1660235d1, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Mon Sep 06 12:35:35 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890184, encodeId=5526189018470, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Apr 11 14:35:35 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900358, encodeId=ae089003584a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/f548240d8bfc479980e63d1c1ca03b30/97576fe32da94dcfbf18dbeb0af5b025.jpg, createdBy=efb62405528, createdName=亚亚Doris, createdTime=Thu Nov 19 08:15:21 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2021-04-11 jml2009
  4. [GetPortalCommentsPageByObjectIdResponse(id=1984524, encodeId=e882198452499, content=<a href='/topic/show?id=7c802892e76' target=_blank style='color:#2F92EE;'>#克隆进化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28927, encryptionId=7c802892e76, topicName=克隆进化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Mon Oct 04 08:35:35 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660235, encodeId=595e1660235d1, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Mon Sep 06 12:35:35 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890184, encodeId=5526189018470, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Apr 11 14:35:35 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900358, encodeId=ae089003584a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201017/f548240d8bfc479980e63d1c1ca03b30/97576fe32da94dcfbf18dbeb0af5b025.jpg, createdBy=efb62405528, createdName=亚亚Doris, createdTime=Thu Nov 19 08:15:21 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2020-11-19 亚亚Doris

    学习了

    0

相关资讯

Lancet:塞利尼索、硼替佐米和地塞米松联合用于一线治疗失败的多发性骨髓瘤患者

对于先前接受过1-3种治疗方案的多发性骨髓瘤患者,每周1次塞利尼索、硼替佐米和地塞米松联合治疗可延长患者无进展生存期

Lancet oncol:RAF-MEK抑制剂在携带RAS/RAF突变的多种肿瘤中的抗肿瘤活性

CH5126766(又名VS-6766,曾用名RO5126766)是一种新型的MEK-pan-RAF抑制剂,已知在多种实体肿瘤中具有抗肿瘤活性;但该药物的推广受毒性限制。现本研究旨在评估CH51267

Lancet Oncol:Venetoclax联合硼替佐米和地塞米松显著改善复发/难治性多发性骨髓瘤患者预后

Venetoclax是一种高选择的、强效口服BCL2抑制剂,可诱导多发性骨髓瘤细胞凋亡。Venetoclax联合硼替佐米和地塞米松在多发性骨髓瘤的1期试验中显现出令人鼓舞的临床疗效和可接受的安全性及耐

JCO:18F-FDG–PET/CT定义多发性骨髓瘤代谢完全缓解的标准

18F-FDG–PET/CT是目前检测多发性骨髓瘤(MM)患者骨髓(BM)外最小残留病灶(MRD)状态的标准方法。该研究旨在定义治疗后PET完全代谢缓解的标准,联合分析了两个独立的欧洲随机

Blood:Isatuximab±地塞米松治疗复发/难治性多发性骨髓瘤

Isatuximab是法国制药巨头赛诺菲(Sanofi)研发的一种靶向浆细胞CD38受体特定表位的IgG1嵌合单克隆抗体,能够触发多种独特的作用机制,包括促进程序性肿瘤细胞死亡(凋亡)和免疫调节活性。